Liquid Biopsy

The European firm will use the funds to commercialize its Naica digital PCR system and develop clinical applications.

The company reported revenues of $21.7 million compared to $11.1 million in the year-ago quarter, overshooting analysts' expectations of $17.5 million.

Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.

The approach, called cfMeDIP-seq, could distinguish early-stage pancreatic cancer from healthy controls and differentiate several types of cancer.

The company reported no revenues in Q3 but said it has completed the transition to a new diagnostic platform for its DetermaVu liquid biopsy lung cancer test.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.